Australia's most trusted
source of pharma news
Posted 11 March 2026 AM
CSL is dropping $1.5 billion to expand its state-of-the-art manufacturing facility in the US based on its business needs, as well as assuaging the Trump Administration in its push to get companies to grow their manufacturing footprint in the US.
The pharma broke ground for the expansion on Monday in Kankakee, Illinois, which will substantially increase its ability to produce life-sustaining, plasma-derived therapies for people living with rare and serious diseases and other acute medical issues.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.